Enlivex Therapeutics Ltd. (ENLV)

NASDAQ: ENLV · IEX Real-Time Price · USD
4.25
+0.11 (2.66%)
Sep 30, 2022 4:00 PM EDT - Market closed
2.66%
Market Cap 78.12M
Revenue (ttm) n/a
Net Income (ttm) -26.30M
Shares Out 18.38M
EPS (ttm) -1.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,345
Open 4.36
Previous Close 4.14
Day's Range 4.14 - 4.42
52-Week Range 3.65 - 9.85
Beta 0.41
Analysts Buy
Price Target 15.30 (+260.0%)
Earnings Date Aug 22, 2022

About ENLV

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel. [Read more...]

Industry Software
IPO Date Dec 12, 1995
CEO Dror Mevorach
Employees 71
Stock Exchange NASDAQ
Ticker Symbol ENLV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ENLV stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 260.00% from the latest price.

Price Target
$15.3
(260.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Enlivex to Present at Upcoming Investor and Media Conferences

Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Compa...

2 weeks ago - GlobeNewsWire

Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Alloc...

Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers

2 weeks ago - GlobeNewsWire

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells

Nes-Ziona, Israel, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophag...

1 month ago - GlobeNewsWire

Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expa...

Nes-Ziona, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that regula...

1 month ago - GlobeNewsWire

Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update

Nes-Ziona, Israel, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today filed with the SEC it...

1 month ago - GlobeNewsWire

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ A...

Nes-Ziona, Israel, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Is...

1 month ago - GlobeNewsWire

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™

Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophag...

1 month ago - GlobeNewsWire

Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combin...

Nes-Ziona, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macroph...

2 months ago - GlobeNewsWire

Enlivex to Present at the 2022 Jefferies Healthcare Conference

Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients ...

3 months ago - GlobeNewsWire

Enlivex Announces Upcoming May Conference Presentations

Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company...

4 months ago - GlobeNewsWire

Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesoth...

Nes-Ziona, Israel, May 09, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, announced the poster present...

4 months ago - GlobeNewsWire

Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra

Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance...

4 months ago - GlobeNewsWire

Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead ...

Nes-Ziona, Israel, April 29, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced its full y...

5 months ago - GlobeNewsWire

Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New Engla...

Publication follows the Israeli Ministry of Health's appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines

11 months ago - GlobeNewsWire

Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021

Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that compa...

1 year ago - GlobeNewsWire

Enlivex Therapeutics (ENLV) Sees Hammer Chart Pattern: Time to Buy?

Enlivex Therapeutics (ENLV) has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy

Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.

1 year ago - Zacks Investment Research

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critica...

Nes-Ziona, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macroph...

1 year ago - GlobeNewsWire

Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Nes-Ziona, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macropha...

1 year ago - GlobeNewsWire

Here's Why Enlivex Therapeutics Ltd. (ENLV) is a Great Momentum Stock to Buy

Does Enlivex Therapeutics Ltd. (ENLV) have what it takes to be a top stock pick for momentum investors?

1 year ago - Zacks Investment Research

Enlivex Therapeutics Stock Jumps On Initiation Of Another Mid-Stage COVID-19 Trial

The Israeli Ministry of Health has signed off Enlivex Therapeutics Ltd's (NASDAQ: ENLV) Phase 2b trial evaluating Allocetra in severe and critical COVID-19 patients with the acute respiratory distressed...

1 year ago - Benzinga

Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomize...

Nes Ziona, Israel, Aug. 15, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today reported that after r...

1 year ago - GlobeNewsWire

Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update

Nes Ziona, Israel, Aug. 09, 2021 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that finan...

1 year ago - GlobeNewsWire

Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manu...

Mr. Palash joins Enlivex from Gamida Cell, where he served as Chief Operating Officer, and previously served as Chief Operating Officer of Protalix Biotherapeutics, and as General Manager of ColBar Life...

1 year ago - GlobeNewsWire

Enlivex to Present at the ARDS Drug Development Summit 2021

Nes Ziona, Israel, July 14, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Co...

1 year ago - GlobeNewsWire